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FUS-DDIT3 is a chimeric oncogene generated by the most com-
15 mon chromosomal translocation t(12;16)(q13;p11) associated to
liposarcomas. The application of transgenic methods and the use
of primary mesenchymal progenitor cells to the study of this
sarcoma-associated FUS-DDIT3 gene fusion have provided insights
into their in vivo functions and suggested mechanisms by which
20 lineage selection may be achieved. These studies indicate that
FUS-DDIT3 contributes to differentiation arrest acting at a point
in the adipocyte differentiation process after induction of perox-
isome proliferator-activated receptor g (PPARg) expression. To
test this idea within a living mouse, we generated mice expressing
25 FUS-DDIT3 within aP2-positive cells, because aP2 is a down-
stream target of PPARg expressed at the immature adipocyte
stage. Here, we report that FUS-DDIT3 expression was success-
fully induced at the aP2 stage of differentiation both in vivo and in
vitro. aP2-FUS-DDIT3 mice do not develop liposarcomas and ex-
30 hibit an increase in white adipose tissue size. Consistent with in
vivo data, mouse embryonic fibroblasts (MEFs) obtained from
aP2-FUS-DDIT3 mice not only were capable of terminal differ-
entiation but also showed an increased capacity for adipogenesis
in vitro compared with wild-type MEFs. Taken together, this study
35 provides genetic evidence that the presence of FUS-DDIT3 in an
aP2-positive cell is not enough to cause liposarcoma development
and establishes that PPARg inactivation is required for
liposarcoma development.
Introduction
40 Myxoid/round cell liposarcoma is the most common subtype of lip-
osarcoma, accounting for 40% of all cases. The tumor cells are
characterized by the chromosomal aberration t(12;16)(q13;p11),
which creates the FUS-DDIT3 oncogene (1–4). This fusion oncogene
has not been found in tumor types other than myxoid/round cell lip-
45 osarcoma (4,5). Due to the absence of a direct link between a cell
carrying the cytogenetic abnormality and a test of whether this cell
has the capacity to maintain the disease in vivo, the nature of the
intimate association between the FUS-DDIT3 oncogene and the phe-
notype with which it is associated is pending to understand (6–8). In
50 vitro the transforming effects of FUS-DDIT3 have been demonstrated
in fibroblasts (9), but curiously not in 3T3-L1 cells under conditions
expected to yield oncogenic effects (10), suggesting that the function
of FUS-DDIT3 is influenced by cell environment. Consistent with this
notion, transgenic mice engineered to express FUS-DDIT3 under the
55control of the ubiquitous E1Fa promoter, which has found to be
functional in mesenchymal progenitor/stem cells (11), developed lip-
osarcomas that resemble their human counterpart (9,12,13). In agree-
ment with this view is the genomic analysis carried out in human
myxoid liposarcoma (14), which is compatible with the genetic pro-
60gram of a primitive target cell from which myxoid liposarcoma could
arise. Further support to this idea comes from the studies showing that
the expression of FUS-DDIT3 in primary mesenchymal progenitor
cells give rise to myxoid liposarcoma-like tumors (11,15). Taken
together, these data indicate that FUS-DDIT3-liposarcoma develops
65from uncommitted progenitor cells (7,8). However, the observation
that FUS-DDIT3 has been previously reported to block terminal dif-
ferentiation of pre-adipocytes in vivo and in vitro (10,16) calls this
hypothesis into question. These reports lead to the hypothesis that
liposarcoma develops from pre-adipocytes carrying FUS-DDIT3 that
70are incapable of terminal differentiation.
While the precise nature of the developmental defect in liposarco-
ma is not yet clear, it is likely FUS-DDIT3 ultimately leads to the
inactivation or antagonism of one or more adipocyte transcriptional
regulatory proteins. The proposed effect of FUS-DDIT3 on peroxi-
75some proliferator-activated receptor c (PPARc) activity (9,12,13,16)
close to the absence of PPARc induction in mesenchymal progenitor/
stem cells expressing FUS-DDIT3 (11) has suggested that FUS-
DDIT3 contributes to differentiation arrest acting at a point in the
adipocyte differentiation process after induction of PPARc expres-
80sion. In order to test this idea and because aP2 is a downstream target
of PPARc (17) which is expressed at the immature adipocyte stage
(18,19), we have generated mice targeting FUS-DDIT3 expression to
aP2-positive cells.
Materials and methods
85Generation of transgenic mice
The cDNA for human FUS-DDIT3 was cloned under the control of the 5.4 kb
aP2 gene promoter for fat-specific FUS-DDIT3-transgenic mice (20) to give
rise to aP2-FUS-DDIT3 cassette. Linear DNA fragments for microinjection
were obtained and injected by the University of Salamanca Transgenic Facility
90into CBAC57BL/6J fertilized eggs. We identified transgenic mice by South-
ern analysis of tail snip DNA after HindIII digestion as described (21). We used
the human DDIT3 cDNA for detection of the transgene. Similar phenotypic
features were seen in all assays for both the aP2-FUS-DDIT3-transgenic lines
generated.
95Reverse transcription–polymerase chain reaction
To analyze expression of human FUS-DDIT3 in mouse tissues and mouse
embryonic fibroblasts (MEFs), reverse transcription was performed according
to the manufacturer’s protocol in a 20 ll reaction containing 50 ng of random
hexamers, 3 lg of total RNA and 200 U of Superscript II RNase H reverse
100transcriptase (Gibco BRL, Madrid, Spain). The sequences of the specific pri-
mers were as follows: FUS-F1: 5#-GGTTATGGCAATCAAGACCAG-3# and
DDIT3-B1: 5#-CTTGCAGGTCCTCATACCAGG-3#. This oligo pair ampli-
fies specifically the fusion region. The thermocycling parameters for the poly-
merase chain reaction and the sequences of the specific primers were as
105follows: 30 cycles at 94C for 1 min, 60C for 1 min and 72C for 1 min.
The polymerase chain reaction products were confirmed by hybridization with
specific probes. Amplification of aP2 and 36B4 served as a control to assess the
adipose tissue and the quality of each RNA sample, respectively.
Histological analysis
110Mice included in this study were subjected to standard necropsy. All major
organs were closely examined under the dissecting microscope, and samples of
each organ were processed into paraffin, sectioned and examined histologi-
cally. All tissue samples were taken from homogenous and viable portions of
the resected sample by the pathologist and fixed within 2–5 min of excision.
115Hematoxylin- and eosin-stained sections of each tissue were reviewed by
a single pathologist (T.F.). For comparative studies, age-matched mice were
used (wild-type versus aP2-FUS-DDIT3 mice).
Abbreviations: BAT, brown adipose tissue; MEF, mouse embryonic fibroblast;
PBS, phosphate-buffered saline; PPARc, peroxisome proliferator-activated
receptor c WAT, white adipose tissue.
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Preparation of primary MEF
Primary embryonic fibroblasts were harvested from 13.5 day post-coitum em-
120 bryos. Head and organs of day 13.5 embryos were dissected; fetal tissue was
rinsed in phosphate-buffered saline (PBS), minced and rinsed twice in PBS.
Fetal tissue was treated with trypsin/ethylenediaminetetraacetic acid and incu-
bated for 30 min at 37C and subsequently dissociated in medium. After removal
of large tissue clamps, the remaining cells were plated out in a 175 cm2 flask.
125 After 48 h, confluent cultures were frozen down. These cells were considered as
being passage 1 MEFs. For continuous culturing, MEF cultures were split 1:3.
MEFs and the /NX ecotropic packaging cell line were grown at 37C in
Dulbeccos-modified Eagle’s medium (Boehringer Ingelheim, Madrid, Spain)
supplemented with 10% heat-inactivated fetal bovine serum (Boehringer Ingel-
130 heim). All the cells were negative for mycoplasma (MycoAlertTM Mycoplasma
Detection Kit, Cambrex, Madrid, Spain).
Adipocyte differentiation
Wild-type and aP2-FUS-DDIT3 MEFs were cultured at 37C in standard
D-MEM:F12 medium (Gibco BRL) supplemented with 10% heat-inactivated
135 fetal bovine serum (Hyclone, Madrid, Spain), 100 U/ml penicillin (BioWhittaker,
Madrid, Spain) and 100 lg/ml streptomycin (BioWhittaker, Madrid, Spain).
Cells (106) of each genotype were plated to 10 cm plastic dishes and propa-
gated to confluence. Two days after confluence, the adipocyte differentiation
program was induced by feeding the cells with standard medium supplemented
140 with 0.5 mM 3-isobutyl-1-methylxanthine (Sigma, Madrid, Spain), 1 lM dexa-
methasone (Sigma) and 5 lg/ml insulin (Sigma) for two days, and then with
standard medium supplemented with 5 lg/ml insulin for 6 days. This medium
was renewed every 2 days. After 8 days, the appearance of cytoplasmic lipid
accumulation was observed by Oil-Red-O staining. Briefly, cells were washed
145 with PBS, and then fixed with 3.7% formaldehyde for 2 min. After a wash with
water, cells were stained with 60% filtered Oil-Red-O stock solution [0.5 g of
Oil-Red-O (Sigma) in 100 ml of isopropanol] for 1 h at room temperature.
Finally, cells were washed twice in water and photographed. To prepare RNA
for northern blotting, cells were harvested at days 0, 2, 4 and 8 of differentiation.
150 RNA extraction
Total RNA was isolated in two steps using TRIzol (Life Technologies, Grand
Island, NY) followed by Rneasy Mini-Kit (Qiagen, Valencia, CA) purification
following the manufacturer’s RNA clean-up protocol with the optional on-
column Dnase treatment. The integrity and the quality of RNA were verified
155 by electrophoresis and its concentration was measured.
Northern blot analysis
Total cytoplasmic RNA (10 lg) of aP2-FUS-DDIT3 MEFs harvested at days 0,
2, 4 and 8 of differentiation and three tumor tissues developed in E1Fa-FUS-
DDIT3-transgenic mice were glyoxylated and fractionated in 1.4% agarose
160 gels in 10 mM Na2HPO4 buffer (pH 7.0). After electrophoresis, the gel was
blotted onto Hybond-N (Amersham, Madrid, Spain), UV cross-linked and
hybridized to 32P-labeled DDIT3 and aP2 probes, respectively. Loading was
monitored by reprobing the filter with a mouse 36B4 probe.
Tumorigenicity assay
165 To test the tumorigenicity of control and aP2-FUS-DDIT3 MEFs at day 2 after
hormonal induction, 4- to 6-week old athymic (nude) male mice were injected
subcutaneously on both flanks with 106 cells re-suspended in 200 ll of PBS.
The animals were examined for tumor formation every week.
Western blot analysis
170 Western blot analysis of white adipose tissue (WAT) was carried out. Extracts
were normalized for protein content by Bradford analysis (Bio-Rad Laborato-
ries, Melville, NY) and Coomassie blue gel staining. Lysates were run on
a 10% sodium dodecyl sulfate–polyacrylamide gel electrophoresis gel and
transferred to a polyvinylidene difluoride membrane. After blocking, the mem-
175 brane was probed with the following primary antibodies: PPARc (H-100 and
E-8, Santa Cruz Biotechnology, Madrid, Spain), RXRa (D-20, Santa Cruz
Biotechnology), C/EBPb (C-19, Santa Cruz Biotechnology), C/EBPd (M-17,
Santa Cruz Biotechnology), C/EBPa (14AA, Santa Cruz Biotechnology) and
actin (I-19, Santa Cruz Biotechnology). Reactive bands were detected with an
180 enhanced chemiluminescence system (Amersham).
Results and discussion
The mouse 5.4 kb promoter fragment of the aP2 gene (20) was used to
drive aP2-directed expression of a human FUS-DDIT3 transgene in
C57BL/6  CBA mice (aP2-FUS-DDIT3 mice) (Figure 1A and B).
185 This promoter is well characterized, and the fragment used contains
all the necessary elements to recapitulate endogenous aP2 gene ex-
pression (20). Thus, by using the aP2 promoter, any possibility that
embryonic expression of FUS-DDIT3 might interfere with develop-
ment was minimized. The FUS-DDIT3 over-expressing animals have
190normal gestation, birth and litter sizes, and they were viable. A num-
ber of founders were generated and two independent lines were ob-
tained. Both lines were used to examine the phenotype further.
Polymerase chain reaction with reverse transcriptase of messenger
RNA for the human transgene confirmed that expression was largely
195confined to aP2-positive mouse tissues [brown adipose tissue (BAT)
and WAT] with no ectopic expression in aP2-negative tissues (Figure
1C). The phenotype described here is therefore due primarily to
expression of the transgene in aP2-postive cells.
Cohorts of transgenic mice were generated to analyze the effect of
200the FUS-DDIT3 gene. aP2-FUS-DDIT3-transgenic mice developed
healthy were fertile and none of the aP2-FUS-DDIT3-transgenic mice
developed liposarcomas in up to 24 months of observation. This result
contrasts with our observations in the FUS-DDIT3-expressing mice,
under the control of the ubiquitous E1Fa promoter, which develop
205liposarcomas (9). Although liposarcomas did not develop in the
aP2-FUS-DDIT3-transgenic mice, the total body weight of adult
aP2-FUS-DDIT3 mice (34.3 ± 1.7 g) was increased compared with
age-matched control mice (29.7 ± 1.2). We investigated whether the
FUS-DDIT3 expression in aP2-positive cells altered WAT develop-
210ment in these mice. We analyzed WAT mass in aP2-FUS-DDIT3
mice. aP2-FUS-DDIT3 mice showed a large increase in WAT weight
(Table I). In addition, food intake was similar in wild-type (2.9 ± 0.4 g
per mouse per day) and aP2-FUS-DDIT3 mice (2.8 ± 0.5 g per mouse
per day). This overall increase in adipose tissue in aP2-FUS-DDIT3
215mice was observed in males and females (Table I). Although white fat
is a non-malignant tissue, it has the capability to quickly proliferate
and expand (22,23). Thus, FUS-DDIT3 expression under aP2 control
regions is inducing those effects. In contrast to WAT, other tissues
including the interscapular BAT and kidney had similar weights for
220wild-type and aP2-FUS-DDIT3 mice (Table I).
To further characterize the phenotype of adipose tissue, we examined
histological sections of WAT and BAT (Figure 2A). We observed no
difference between the wild-type and aP2-FUS-DDIT3 mice in the
BAT and WAT tissues. The histological analyses of the WAT in aP2-
225FUS-DDIT3 mice did not evidence any pathological change within the
terminally differentiated adipocytes. On the contrary, aP2-FUS-DDIT3
Fig. 1. aP2-FUS-DDIT3 mice: transgene construct and expression in
adipose tissues. (A) Schematic representation of the aP2-FUS-DDIT3 vector
used in this study. (B) Identification of transgenic mice by Southern analysis
of tail snip DNA after HindIII digestion. We used the cDNA for human
DDIT3 for detection of the transgene. (C) Expression of the aP2-FUS-DDIT3
transgene was demonstrated by reverse transcription–polymerase chain
reaction. Expression of FUS-DDIT3 was analyzed by reverse transcription–
polymerase chain reaction in tissues derived of aP2-FUS-DDIT3 mice. 36B4
and aP2 were used to check cDNA integrity and loading and adipose tissue
identification, respectively.
P.A.Pe´rez-Mancera et al.
2
mice had a normal architecture of the tissue and we did not observe
any shift in the WAT toward immature in the aP2-FUS-DDIT3 mice.
Some aP2-FUS-DDIT3 animals presented adipocytic accumulation in
230 liver (Figure 2B). The above results support the hypothesis that FUS-
DDIT3 expression modulates adipose tissue size. To further explore
the molecular basis through which FUS-DDIT3 expression in aP2-
positive cells impairs the development of fat tissue, we examined the
expression levels of the proteins responsible for WAT development.
235The expression of RXRa, C/EBPd, C/EBPb, PPARc and C/EBPa was
not affected (Figure 2C).
The adipogenesis of MEFs by hormonal induction is a well-
established model system for the study of adipocyte differentiation
in vitro (19). To further examine the contribution of FUS-DDIT3 to
240adipogenesis, we isolated MEFs from day 13.5 of aP2-FUS-DDIT3
and control embryos (Figure 3). FUS-DDIT3 expression is not present
in uncommitted progenitor cells before differentiation treatment (Fig-
ure 3A). However, the amount of FUS-DDIT3 mRNA was apparent
within 2 days and increased in abundance in parallel to aP2 expression
245(Figure 3A). These results indicate that aP2-FUS-DDIT3 is tightly
controlled temporally and spatially during differentiation of uncom-
mitted mesenchymal cells. At day 8 after hormonal induction, there is
lipid accumulation in control MEFs (20–30%). However, there was
extensive accumulation in aP2-FUS-DDIT3 MEFs (45–55%) (Figure
2503B). The amount of FUS-DDIT3 mRNA in aP2-FUS-DDIT3 was
similar to the expression of FUS-DDIT3 in tumors of E1Fa-FUS-
DDIT3 mice (Figure 3C). To test the putative malignant nature of
these cells, 1  106 aP2-FUS-DDIT3 MEFs at day 2 after hormonal
induction (when the amount of FUS-DDIT3 mRNA was apparent)
255were injected subcutaneously into 40-day-old nude mice. Mice in-
jected resulted in no tumors. These results show that adipocyte dif-
ferentiation was not blocked in MEFs derived from aP2-FUS-DDIT3-
transgenic mice treated with adipogenic hormones and confirm that
interference with the normal process of differentiation contributes to
260the oncogenic potential of FUS-DDIT3 fusion protein (9).
Fig. 2. Histologic appearance of adipose tissues in aP2-FUS-DDIT3-transgenic mice. (A) Hematoxylin–eosin-stained sections of the liver tissues coming from
control and aP2-FUS-DDIT3 mice. Liver of aP2-FUS-DDIT3 mice shows hepatic steatosis. (B) Hematoxylin–eosin-stained sections of interscapular BAT and
reproductive WAT from control and aP2-FUS-DDIT3 mice. The size of cells in aP2-FUS-DDIT3 WAT was similar to control cells. (C) Western blot analyses of
regulators of adipocyte function in WAT of control mice and aP2-FUS-DDIT3 mice.
Table I. Adipose tissue mass in aP2-FUS-DDIT3 mice
Kidney Reproductive
fat pad
Inguinal
fat pad
Retroperitoneal
fat pad
Male
Control 0.147 ± 0.009 0.78 ± 0.13 0.56 ± 0.10 0.30 ± 0.08
aP2-FUS-
DDIT3
0.147 ± 0.010 1.89 ± 0.19 1.58 ± 0.15 0.87 ± 0.09
Female
Control 0.143 ± 0.007 not determined 0.55 ± 0.07 0.38 ± 0.09
aP2-FUS-
DDIT3
0.144 ± 0.009 not determined 1.71 ± 0.13 1.09 ± 0.16
Mice were 6 months old. Weights are given in grams. Values are
means ± SEMs from five mice in each group. Differences between control
and aP2-FUS-DDIT3 were statistically significant (P , 0.01) as determined
by Mann–Whitney’s test.
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In conclusion, this study provides genetic evidence that the presence
of FUS-DDIT3 in an aP2-positive cell is not enough to cause liposar-
coma development and these cells are capable of terminal differentia-
tion, underscoring the relevance of relationship between FUS-DDIT3
265 and the cell environment. Moreover, although it has been suggested that
FUS-DDIT3 transforms at a point in the differentiation process after
induction of PPARc expression, our findings further establish that
PPARc inactivation is required for liposarcoma development. The pre-
cise mechanism whereby FUS-DDIT3 contributes to PPARc inactiva-
270 tion and differentiation arrest, however, remain to be elucidated.
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